BACKGROUND: We are developing a very small, innovative, continuous-flow total artificial heart (CFTAH) that passively self-balances left and right pump flows and atrial pressures without sensors. This report details the CFTAH design concept and our initial in vitro data. METHODS: System performance of the CFTAH was evaluated using a mock circulatory loop to determine the range of systemic and pulmonary vascular resistance (SVR and PVR) levels over which the design goal of a maximum absolute atrial pressure difference of 10 mm Hg is achieved for a steady-state flow condition. Pump speed was then modulated at 2,600 +/- 900 rpm to induce flow and arterial pressure pulsation to evaluate the effects of speed pulsations on the system performance. An automatic control mode was also evaluated. RESULTS: Using only passive self-regulation, pump flows were balanced and absolute atrial pressure differences were maintained at <10 mm Hg over a range of SVR (750 to 2,750 dyne.sec.cm(-5)) and PVR (135 to 600 dyne.sec.cm(-5)) values far exceeding normal levels. The magnitude of induced speed pulsatility affected relative left/right performance, allowing for an additional active control to improve balanced flow and pressure. The automatic control mode adjusted pump speed to achieve targeted pump flows based on sensorless calculations of SVR and CFTAH flow. CONCLUSIONS: The initial in vitro testing of the CFTAH with a single, valveless, continuous-flow pump demonstrated its passive self-regulation of flows and atrial pressures and a new automatic control mode. Copyright (c) 2010 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
BACKGROUND: We are developing a very small, innovative, continuous-flow total artificial heart (CFTAH) that passively self-balances left and right pump flows and atrial pressures without sensors. This report details the CFTAH design concept and our initial in vitro data. METHODS: System performance of the CFTAH was evaluated using a mock circulatory loop to determine the range of systemic and pulmonary vascular resistance (SVR and PVR) levels over which the design goal of a maximum absolute atrial pressure difference of 10 mm Hg is achieved for a steady-state flow condition. Pump speed was then modulated at 2,600 +/- 900 rpm to induce flow and arterial pressure pulsation to evaluate the effects of speed pulsations on the system performance. An automatic control mode was also evaluated. RESULTS: Using only passive self-regulation, pump flows were balanced and absolute atrial pressure differences were maintained at <10 mm Hg over a range of SVR (750 to 2,750 dyne.sec.cm(-5)) and PVR (135 to 600 dyne.sec.cm(-5)) values far exceeding normal levels. The magnitude of induced speed pulsatility affected relative left/right performance, allowing for an additional active control to improve balanced flow and pressure. The automatic control mode adjusted pump speed to achieve targeted pump flows based on sensorless calculations of SVR and CFTAH flow. CONCLUSIONS: The initial in vitro testing of the CFTAH with a single, valveless, continuous-flow pump demonstrated its passive self-regulation of flows and atrial pressures and a new automatic control mode. Copyright (c) 2010 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.
Authors: Keiji Kamohara; Stephan Weber; Ryan S Klatte; Viviane Luangphakdy; Christine R Flick; Yoshio Ootaki; Masatoshi Akiyama; Faruk Cingoz; Chiyo Ootaki; Michael W Kopcak; Jenny Liu; Ji-Feng Chen; Jose L Navia; William A Smith; Kiyotaka Fukamachi Journal: Artif Organs Date: 2007-09 Impact factor: 3.094
Authors: Keiji Kamohara; Stephan Weber; Ryan S Klatte; Yoshio Ootaki; Masatoshi Akiyama; Michael W Kopcak; Viviane Luangphakdy; Christine R Flick; Ji-Feng Chen; Jose L Navia; William A Smith; Kiyotaka Fukamachi Journal: ASAIO J Date: 2006 Jul-Aug Impact factor: 2.872
Authors: Leslie W Miller; Francis D Pagani; Stuart D Russell; Ranjit John; Andrew J Boyle; Keith D Aaronson; John V Conte; Yoshifumi Naka; Donna Mancini; Reynolds M Delgado; Thomas E MacGillivray; David J Farrar; O H Frazier Journal: N Engl J Med Date: 2007-08-30 Impact factor: 91.245
Authors: Saleem Haj-Yahia; Emma J Birks; Paula Rogers; Christopher Bowles; Mandy Hipkins; Robert George; Mohammed Amrani; Mario Petrou; John Pepper; Gilles Dreyfus; Asghar Khaghani Journal: J Thorac Cardiovasc Surg Date: 2007-07 Impact factor: 5.209
Authors: Donald Esmore; David Kaye; Phillip Spratt; Robert Larbalestier; Peter Ruygrok; Steven Tsui; Deborah Meyers; Arnt E Fiane; John Woodard Journal: J Heart Lung Transplant Date: 2008-04-23 Impact factor: 10.247
Authors: Jennifer Cowger Matthews; Todd M Koelling; Francis D Pagani; Keith D Aaronson Journal: J Am Coll Cardiol Date: 2008-06-03 Impact factor: 24.094
Authors: K Fukamachi; A L Massiello; R J Kiraly; J F Chen; S Himley; C Davies; F Fukumura; K Muramoto; E Olsen; L A Golding Journal: ASAIO J Date: 1993 Jul-Sep Impact factor: 2.872
Authors: Takuma Miyamoto; David J Horvath; Dennis W Horvath; Jamshid H Karimov; Nicole Byram; Barry D Kuban; Kiyotaka Fukamachi Journal: ASAIO J Date: 2019-08 Impact factor: 2.872
Authors: Mariko Kobayashi; David J Horvath; Nicole Mielke; Akira Shiose; Barry Kuban; Mark Goodin; Kiyotaka Fukamachi; Leonard A R Golding Journal: Artif Organs Date: 2012-07-02 Impact factor: 3.094